- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05896787
Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
June 1, 2023 updated by: Feng Wang, The First Affiliated Hospital of Zhengzhou University
A Phase II Study of Candonilimab (AK104) Combined With Preoperative Chemotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
This is a prospective, single-arm, open-label,multi-center, phase II study, aiming to evaluate the efficacy and safety of AK104 combined with preoperative chemotherapy in patients with locally advanced ESCC.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Eligible patients first receive AK104 (10mg/kg, iv, Q2W) for one cycle in the induction period, and then patients receive AK104 (10mg/kg, iv, Q3W) combined with nab-paclitaxel (130mg/m2 ivgtt d1,d8, Q3W) and carboplatin ((AUC=5) d1,Q3W) for 2 cycles.
After neoadjuvant therapy of 3 cycles, patient will undergo preoperative evaluation.
For patients who can be performed for R0 surgery, surgery wil be performed in 4 to 6 weeks.
Patients who do not achieve Pathological complete response (pCR) will receive AK104 (10mg/kg, iv, Q3W) as adjuvant therapy until disease progression or intolerable toxicity for up to 12 months.
Patients who achieve pCR after surgery will be enrolled in observational follow-up.
Study Type
Interventional
Enrollment (Estimated)
45
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Feng Wang
- Phone Number: 13938244776
- Email: fengw010@163.com
Study Locations
-
-
Henan
-
Anyang, Henan, China, 450052
- Anyang Cancer Hospital
-
Contact:
- Anlin Hao
-
Zhengzhou, Henan, China, 450052
- Feng Wang
-
Contact:
- Feng Wang
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Voluntarily signing a written informed consent form;
- Males or females aged ≥ 18 to ≤ 70 years;
- ECOG score 0-1;
- Pathologically diagnosed thoracic esophageal squamous cell carcinoma;
- No distant metastasis after imaging examination, and esophageal cancer can be resected or potentially resectable with stage cT1b-cT2N+M0 or cT3-cT4a anyN M0 or cT2N0M0 high-risk (lymphovascular invasion or tumor ≥3 cm or hypo-differentiation) (AJCC 8th edition cTNM stage);
- Not received prior antitumor therapy (surgery, radiotherapy, chemotherapy, immunotherapy, etc. for esophageal cancer);
- Life expectancy is greater than 6 months;
- At least one measurable tumor lesion per RECIST v1.1;
- Major organ functions are adequate;
Exclusion Criteria:
- Patient has received previous antitumor therapy (chemotherapy, radiation, surgery or immunotherapy);
- Cervical or thoracic esophageal cancer is < 5 cm from the cricopharyngeal muscle;
- Patients are or are expected to be at significant risk of esophageal perforation, fistula, and major bleeding;
- Imaging during the screening period showed that the tumor surrounded or invaded important blood vessels or organs (such as the heart and pericardium, trachea, aorta, superior vena cava, etc.) or there was obvious necrosis or cavity, and the investigator determined that entering the study would cause bleeding risk; participants at risk of developing oesophageal or oesophageal fistula;
- Patients with a history of other malignant diseases in the last 5 years,unless complete resolution or no additional treatment is required (exceptions include, but are not limited to, basal or squamous cell skin cancer, superficial bladder cancer or prostate, cervix, or breast carcinoma in situ);
- Pregnant or nursing women;
- Patients with known or suspected active autoimmune disease;
- Patients with a history of myocarditis, cardiomyopathy, malignant arrhythmias;
- Other patients are not eligible for enrollment assessed by investigators;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AK104 plus nab-paclitaxel and carboplatin
In the induction period, AK104 (10mg/kg, iv, Q2W) is given for one cycle; and then AK104 (10mg/kg, iv, Q3W) is combined with nab-paclitaxel (130mg/m2 ivgtt d1,d8, Q3W) and carboplatin ((AUC=5) d1,Q3W) for 2 cycles; After R0 surgery, AK104 (10mg/kg, iv, Q3W) is given as adjuvant therapy for up to 12 months for those who do not achieve pCR. |
AK104 plus nab-paclitaxel and carboplatin as neoadjuvant therapy,and AK104 as adjuvant therapy for those who do not achieve pCR;
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pCR
Time Frame: up to 2 years
|
Pathological complete response
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MPR
Time Frame: up to 2 years
|
Major pathologic response
|
up to 2 years
|
R0 resection rate
Time Frame: up to 2 years
|
R0 resection rate
|
up to 2 years
|
Downstaging rate
Time Frame: up to 2 years
|
Downstaging rate
|
up to 2 years
|
DFS
Time Frame: up to 2 years
|
Disease-free survival
|
up to 2 years
|
OS
Time Frame: up to 2 years
|
Overall survival
|
up to 2 years
|
AE
Time Frame: up to 2 years
|
Adverse event
|
up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Feng Wang, The First Affiliated Hospital of Zhengzhou University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
August 1, 2023
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
August 1, 2026
Study Registration Dates
First Submitted
June 1, 2023
First Submitted That Met QC Criteria
June 1, 2023
First Posted (Actual)
June 9, 2023
Study Record Updates
Last Update Posted (Actual)
June 9, 2023
Last Update Submitted That Met QC Criteria
June 1, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Esophageal Neoplasms
- Carcinoma
- Carcinoma, Squamous Cell
- Esophageal Squamous Cell Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Carboplatin
- Paclitaxel
Other Study ID Numbers
- L2023-K003-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Squamous Cell Carcinoma
-
Cancer Institute and Hospital, Chinese Academy...Akeso Pharmaceuticals, Inc.Not yet recruitingMetastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
-
National Cancer Institute (NCI)TerminatedEsophageal Cancer | Esophageal Neoplasms | Esophageal Adenocarcinoma | Squamous Cell Carcinoma | Esophageal Squamous Cell CancerUnited States
-
Peking UniversityUnknownAdvanced Esophageal Squamous CarcinomaChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
Fujian Medical University Union HospitalNot yet recruitingEsophageal Squamous Cell Carcinoma Thoracic Stage II | Esophageal Squamous Cell Carcinoma Thoracic Stage III | Esophageal Squamous Cell Carcinoma Thoracic Stage IVChina
-
The First Affiliated Hospital of Henan University...Luoyang Central Hospital; Nanyang Central Hospital; Sanmenxia Central Hospital; Military 150 Hospital and other collaboratorsActive, not recruitingStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell CarcinomaChina
-
Jiangsu Cancer Institute & HospitalRecruitingLocally Advanced Esophageal CarcinomaChina
-
Shanghai Zhongshan HospitalZhejiang Cancer Hospital; Sun Yat-sen University; Cancer Institute and Hospital... and other collaboratorsRecruitingEsophageal Squamous Cell Carcinoma Stage II | Esophageal Squamous Cell Carcinoma Stage IIIChina
-
The First Affiliated Hospital of Henan University...UnknownStage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell Carcinoma | Stage I Esophageal Adenocarcinoma | Stage II Esophageal Adenocarcinoma | Stage III Esophageal Adenocarcinoma | Stage I Esophageal Squamous Cell CarcinomaChina
Clinical Trials on AK104, nab-paclitaxel, carboplatin
-
Xiaohua WuRecruitingCervical Cancer | Neoadjuvant Immunotherapy | Fertility-sparing SurgeryChina
-
Shengjing HospitalRecruiting
-
AkesoCompletedLung Cancer Non-Small Cell Stage IIIB/IIIC/IVChina
-
Hebei Medical University Fourth HospitalBeijing 302 Hospital; CSPC Ouyi Pharmaceutical Co., Ltd.UnknownTriple Negative Breast Cancer | Nab-paclitaxelChina
-
Shengjing HospitalRecruitingBreast Cancer | Immunotherapy | Stereotactic RadiotherapyChina
-
West China HospitalNot yet recruiting
-
Women's Hospital School Of Medicine Zhejiang UniversitySun Yat-sen University; Qilu Hospital of Shandong University; Second Affiliated... and other collaboratorsRecruitingEpithelial Ovarian Carcinoma Stage III | Epithelial Ovarian Carcinoma Stage IV | Fallopian Tube Carcinoma Stage III | Fallopian Tube Carcinoma Stage IV | Primary Peritoneal Carcinoma Stage III | Primary Peritoneal Carcinoma Stage IVChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingInflammatory Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor NegativeUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityGuangdong Provincial People's Hospital; Third Affiliated Hospital, Sun Yat-Sen...RecruitingLung Cancer, Non-small Cell | Artificial IntelligenceChina
-
Hebei Medical University Fourth HospitalBeijing 302 Hospital; CSPC Ouyi Pharmaceutical Co., Ltd.UnknownBreast Cancer | Triple-negative Breast Cancer | Nab-paclitaxelChina